Clinical trial · Interventional
Remote Ischemic Conditioning in Oncology
Remote Ischemic Conditioning for Protection from Treatment-related Cardiotoxicity in Pediatric, Adolescent, and Young Adult Patients Undergoing Anthracycline Chemotherapy
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This is a feasibility study at a single site, Cincinnati Children's Hospital Medical Center. Patients undergoing anthracycline chemotherapy for Hodgkin disease and soft-tissue and bone sarcoma who meet eligibility requirements will be approached to participate in the study. The purpose of the study is to determine if performing remote ischemic conditioning (RIC) is feasible in children and young adults receiving anthracycline chemotherapy. The secondary purpose is to describe differences in markers of myocardial injury and stress in children and young adults that receive RIC prior to anthracycline chemotherapy compared to control subjects that receive sham therapy prior to chemotherapy.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Participants Undergoing Anthracycline Chemotherapy | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| autoRIC® | Device | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- Therapeutic Group
- description
- With the patient sitting upright in bed or a chair, the remote ischemic conditioning intervention will consist of 4 automatic cycles of upper arm blood pressure cuff inflation to 200 mm Hg for 5 minutes to induce transient, noninjurious, limb ischemia, followed by cuff deflation for 5 minutes, for a total of 35 minutes (autoRIC®, Cellaegis Devices, Mississauga, ON, Canada). The remote ischemic preconditioning cycles will be performed by trained research personnel prior to each cycle of chemotherapy (total treatments variable based on chemotherapy protocol).
- interventionNames
- Device: autoRIC®
- type
- NO_INTERVENTION
- label
- Control Group
- description
- A control group will undergo a similar procedure, but the cuff will not be inflated.
Primary outcomes (1)
- measure
- Adverse Effects
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 11 Years
Show eligibility criteria text
Inclusion Criteria: 1. Pediatric, adolescent, or young adult patients, 11 years of age or above. 2. Able to tolerate upper arm blood pressure inflation. Exclusion Criteria: 1. Previous diagnosis of cardiomyopathy (dilated, hypertrophic, restrictive, myocarditis) or congenital heart disease other than bicuspid aortic valve. 2. Chronic kidney disease as defined as a pre-transplant GFR \<80 3. Central line in both upper extremities. 4. Known peripheral vascular disease or vasculitis. 5. Platelet count less than 30,000. 6. Known clotting disorder or hypercoagulability 7. Non-English-speaking patients.
References
Publications (0)
Data not yet available